London, United Kingdom
Mestag Therapeutics, founded in 2020 and headquartered in the United Kingdom, is at the forefront of developing innovative treatments for inflammatory diseases and cancer. Utilizing its expertise in fibroblast immunology, Mestag is advancing a strategic pipeline of first-in-class antibody programs that promise significant breakthroughs in healthcare.
The company's distinctive approach to fibroblast-immune interactions sets it apart in the Biotechnology and Health Care sectors, potentially offering new, targeted treatment options. This focus positions Mestag well in the growing market for specialized therapies.
With its slogan, "New therapies for inflammatory disease and cancer by targeting fibroblast immunology," Mestag signals its mission and innovative edge. The firm is backed by reputable investors, such as SV Health Investors and Johnson & Johnson Innovation – JJDC, who contributed to its last investment round of $11.00M on 20 April 2021. These investments highlight confidence in Mestag's vision and potential growth trajectory in a competitive industry.
